Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Enalapril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 14/20 | 0.91 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.91 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enalapril SCHEMBL20817249 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL10 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL2719411 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL9 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL10390115 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL1650291 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL308603 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL825430 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL9019924 | 0.99 | SMN1; SMN2 (0.98) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL9019927 | 0.99 | SMN1; SMN2 (0.98) | SMN1; SMN2ACELMNAABCB11MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0967221-B1 | PROCESS FOR PREPARING PHARMACOLOGICALLY ACCEPTABLE SALTS OF N-(1(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-L-ALANYL AMINO ACIDS | KANEKA CORP (JP) | 2005-05-25 | — | — | EP | claimed |
| US-6713628-B2 | BY-PRODUCT INHIBITION OF THE DIKETOPIPERAZINE DERIVATIVE BY CARRYING OUT IN AQUEOUS LIQUID A SERIES OF OPERATIONS UNDER GIVEN CONDITIONS IN THE SAME SOLVENT; MAKING ENALAPRIL MALEATE FOR EXAMPLE | KANEKA CORPORATION (JP) | 2004-03-30 | — | — | US | claimed |
| US-20030105327-A1 | Process for preparing pharmacologically acceptable salt of N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-amino acid | KANEKA CORPORATION (JP) | 2003-06-05 | — | — | US | claimed |
| US-6541635-B1 | Silylprotected L-proline derivative or salt is deprotected in presence of a nonaqueous medium containing an organic solvent at a temperature of 5 degree C. to 40 degree C. | EVERLIGHT USA, INC. | 2003-04-01 | — | — | US | claimed |
| US-20020087007-A1 | Process for preparing pharmacologically acceptable salt of N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-amino acid | KANEKA CORPORATION (JP) | 2002-07-04 | — | — | US | claimed |
| EP-0967221-A1 | PROCESS FOR PREPARING PHARMACOLOGICALLY ACCEPTABLE SALTS OF N-(1(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-L-ALANYL AMINO ACIDS | KANEKA CORPORATION (JP) | 1999-12-29 | — | — | EP | claimed |
| US-5977380-A | Process for preparing N-[1- (S)-ethoxycarbonyl-3- phenylpropyl]-L-alanine derivatives | EVERLIGHT USA, INC. (US) | 1999-11-02 | — | — | US | claimed |
| EP-0463636-A2 | Cardiovascular composition | MERCK FROSST CANADA INC. (CA) | 1992-01-02 | — | — | EP | claimed |
| US-5001113-A | Di- or tripeptide renin inhibitors containing lactam conformational restriction in ACHPA | MERCK & CO., INC. (US) | 1991-03-19 | — | — | US | claimed |
| EP-0389127-A1 | Renin-inhibitory di-, tri-, and tetrapeptides | MERCK & CO. INC. (US) | 1990-09-26 | — | — | EP | claimed |
| US-4782043-A | HYPOTENSIVES | MERCK & CO., INC. (US) | 1988-11-01 | — | — | US | claimed |
| EP-0278158-A2 | Renin inhibitors containing phenylalanyl-histidine replacements | MERCK & CO. INC. (US) | 1988-08-17 | — | — | EP | claimed |
| EP-0209897-A2 | Peptide enzyme inhibitors | MERCK & CO. INC. (US) | 1987-01-28 | — | — | EP | claimed |
| EP-0166257-A2 | Cardiovascular composition | MERCK FROSST CANADA INC. (CA) | 1986-01-02 | — | — | EP | claimed |
| EP-0163237-A2 | Di- and tri-peptidal renin inhibitors | MERCK & CO. INC. (US) | 1985-12-04 | — | — | EP | claimed |
| EP-0156318-A2 | C-terminal amide cyclic renin inhibitors containing peptide isosteres | MERCK & CO. INC. (US) | 1985-10-02 | — | — | EP | claimed |
| EP-0156322-A2 | Renin inhibitors containing peptide isosteres | MERCK & CO. INC. (US) | 1985-10-02 | — | — | EP | claimed |
| EP-0129189-A2 | Renin inhibitors containing a C-terminal amide cycle and compositions and combinations containing the same | MERCK & CO. INC. (US) | 1984-12-27 | — | — | EP | claimed |
| US-4472384-A | INTERPHENYLENE 9-THIA-11-OXO-12-AZA PROSTANOIC ACID DERIVATIVE AND CARBOXYALKYLDIPEPTIDE | MERCK & CO., INC. (US) | 1984-09-18 | — | — | US | claimed |
| US-4374829-A | Aminoacid derivatives as antihypertensives | MERCK & CO., INC. (US) | 1983-02-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105327-A1 | Process for preparing pharmacologically acceptable salt of N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-amino acid | SLC7A1, ASS1, ALDH7A1 | ACE 67/4885SMN1; SMN2 496/4885LMNA 765/4885 |
| US-20020087007-A1 | Process for preparing pharmacologically acceptable salt of N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-amino acid | SLC7A1, ASS1, ALDH7A1 | ACE 67/4885SMN1; SMN2 496/4885LMNA 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.